Shuttle Pharmaceuticals is a small, pre-revenue public company in the process of pivoting its business. In late 2025, Shuttle acquired the assets of Molecule.ai, an AI-driven drug discovery software platform, and simultaneously wound down its prior core business — clinical development of its lead drug candidate, Ropidoxuridine. The Molecule.ai platform is designed to assist pharmaceutical researchers in early-stage drug discovery through three core capabilities: molecular property prediction using transformer-based AI models, cross-molecule evaluation to compare candidates across multiple properties simultaneously, and a reasoning module that uses LLMs to contextualize and explain predictions in actionable terms. The platform is built on a unified inference engine with an API-first integration layer, emphasizing reproducibility and traceability — qualities important in regulated research environments. Shuttle intends to use Molecule.ai as the foundation for a new drug discovery and development business, but has not yet disclosed whether it will pursue a software licensing model, develop proprietary drug candidates internally, or both. The company has only two full-time employees, has been funded entirely through equity raises, and is effectively starting over following the pivot. Shuttle has faced repeated Nasdaq compliance issues and its financial position remains thin.